Sobi Targets Thrombocytopenia In $915m Swoop For Dova

30 Sep 2019

• By Kevin Grogan

The Swedish group has got hold of the ITP and CLD drug Doptelet, widening its hematology business beyond hemophilia.

Butterflies — Sobi of Sweden hopes to fly higher buying Dova of the US • Source: Shutterstock

More from Deals

More from Business